RE:RE:RE:RE:OVARIAN CANCER UPDATE
A bit of digging around this morning puts my best guess at Takeda.
https://www.takeda.com/
Dr. David Huntsman has previously worked closely with Dr. Cashman.
Check out this NR from a few years ago announcing a collboration between BCCA and Takeda.
https://www2.news.gov.bc.ca/news_releases_2009-2013/2010PREM0110-000585.htm
From today's NR:
These studies were performed using the ES-2 ovarian clear cell carcinoma (OCCC) tumor model. Clear cell carcinoma accounts for 5-13% of ovarian cancer cases in Western populations and 15-25% of cases
Japan. OCCC has been shown to be associated with a poorer prognosis and is relatively resistant to conventional platinum-based chemotherapy when compared to other types of ovarian cancer. Thus, there is a great need for novel OCCC therapies.
From the 2010 NR announcing collaboration between BCCA and Takeda:
“This unique partnership will focus Takeda’s drug development capacity on specific abnormalities identified in ovarian cancers,” said Dr. David Huntsman, director of the ovarian cancer research program at the BC Cancer Agency and Vancouver Coastal Health Research Institute, and professor, department of pathology and laboratory medicine, UBC. “We need new approaches to treat the many subtypes of ovarian cancer and we look forward to working with Takeda scientists to translate our genomic discoveries into better outcomes for women with this cancer.”
Just something to mull over. Thoughts?